Innate Pharma SA
PAR:IPH
Innate Pharma SA
PAR:IPH
Price:
1.194
EUR
8.15%
Market Cap:
€111.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Innate Pharma SA
PAR:IPH
|
FR |
|
S
|
SM Life Design Group Co Ltd
KOSDAQ:063440
|
KR |
|
Bhansali Engg Polymers Ltd
NSE:BEPL
|
IN |
|
Bilendi SA
PAR:ALBLD
|
FR |
|
Seanergy Maritime Holdings Corp
NASDAQ:SHIP
|
GR |
|
Searchlight Resources Inc
XTSX:SCLT
|
CA |
|
Composite Alliance Group Inc
XTSX:CAG
|
CA |
|
6
|
60 Degrees Pharmaceuticals Inc
NASDAQ:SXTP
|
US |
|
Corporate Travel Management Ltd
ASX:CTD
|
AU |
|
Logan Ridge Finance Corp
NASDAQ:LRFC
|
US |
|
Mediaset Espana Comunicacion SA
F:RWW
|
ES |
|
Devonian Health Group Inc
XTSX:GSD
|
CA |
|
Metasphere Labs Inc
OTC:LABZD
|
CA |
|
Carlisle Companies Inc
NYSE:CSL
|
US |
|
Dassault Systemes SE
PAR:DSY
|
FR |
|
Wismilak Inti Makmur Tbk PT
IDX:WIIM
|
ID |
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
US |
|
Cielo Waste Solutions Corp
XTSX:CMC
|
CA |
|
S
|
SPO Global Inc
OTC:SPOM
|
US |
|
I
|
IBI-Lion SOCIMI SA
MAD:YIBI
|
ES |
|
Kering SA
PAR:KER
|
FR |
|
Public Bank Bhd
KLSE:PBBANK
|
MY |
|
Integrated Rail and Resources Acquisition Corp
OTC:IRRX
|
US |
|
Thomson Medical Group Ltd
SGX:A50
|
SG |
Multiples-Based Value
The Multiples-Based Value of one
IPH
stock under the Base Case scenario is
hidden
EUR.
Compared to the current market price of 1.194 EUR,
Innate Pharma SA
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IPH Multiples-Based Value
LOCKED
Multiples Across Competitors
IPH Competitors Multiples
Innate Pharma SA Competitors
Innate Pharma SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Innate Pharma SA
PAR:IPH
|
110.1m EUR | 39.5 | -2.2 | -1.7 | -1.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
374.1B USD | 6.1 | 89.4 | 14.8 | 20.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188.5B USD | 5.1 | 24.4 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
175.7B USD | 6 | 20.7 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.8B USD | 9.4 | 28.5 | 21.4 | 22.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.5B EUR | 11.7 | 37.5 | 40.4 | 41.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.5B AUD | 3 | 33.2 | 11.2 | 14 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
